Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone
Plus, news about Diakonos Oncology and Coherus: Roche’s longer-term data for multiple sclerosis drug: The Swiss drugmaker’s BTK inhibitor fenebrutinib achieved an annualized relapse rate of 0.06 in 93 people with ...
Plus, news about Diakonos Oncology and Coherus:
Roche’s longer-term data for multiple sclerosis drug: The Swiss drugmaker’s BTK inhibitor fenebrutinib achieved an annualized relapse rate of 0.06 in 93 people with ...
